(0.32%) 5 116.44 points
(0.31%) 38 358 points
(0.38%) 15 988 points
(-0.97%) $83.04
(5.36%) $2.03
(0.34%) $2 355.10
(0.54%) $27.68
(4.26%) $961.35
(-0.27%) $0.932
(-0.44%) $10.98
(-0.59%) $0.796
(1.63%) $93.37
Live Chart Being Loaded With Signals
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins...
Stats | |
---|---|
本日の出来高 | 1 171.00 |
平均出来高 | 3 000.00 |
時価総額 | 118.28M |
EPS | $0 ( 2024-03-14 ) |
次の収益日 | ( $0 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.740 |
ATR14 | $0 (0.00%) |
Molecular Partners AG 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Molecular Partners AG 財務諸表
Annual | 2023 |
収益: | $7.04M |
総利益: | $-40.81M (-579.80 %) |
EPS: | $-1.890 |
FY | 2023 |
収益: | $7.04M |
総利益: | $-40.81M (-579.80 %) |
EPS: | $-1.890 |
FY | 2022 |
収益: | $189.56M |
総利益: | $138.81M (73.23 %) |
EPS: | $3.63 |
FY | 2021 |
収益: | $9.33M |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.06 |
Financial Reports:
No articles found.
Molecular Partners AG
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。